Global LHRH for Prostate Treatment Market Size, Share and Trends Analysis Report, By Type (Leuprolide, Goserelin, and Triptorelin, Forecast Period (2022-2028)

The global LHRH for prostate treatment market is anticipated to grow at a CAGR of 8.1% during the forecast period (2022-2028). Patients’ awareness of healthcare facilities is growing, as are the incidence rates of prostate cancer in the globe. Patients are increasingly preferring self-pay therapy due to technological advancements that have resulted in the least intrusive procedures. The market is likely to rise as new drug delivery technologies are developed for improved treatment response and effective management of side effects associated with LHRH therapy. LHRH for prostate treatment is a sort of medication that helps men with advanced prostate cancer block the production and release of specific hormones. It works by lowering testosterone levels, which can help cancer cells grow and spread more slowly or entirely stop.

Since conditions related to aging, including obesity and diabetes, are becoming more prevalent, the use of LHRH for prostate treatment in individuals over 75 years old is growing. Men with advanced hormone-dependent cancer of the prostate should take LHRH for prostate therapy. The medicine works by lowering testosterone levels, which can lead to tumor shrinkage or stabilization, as well as a reduction in cancer symptoms. Prostate cancer affects one out of every eight men at some point in their lives, according to the American Cancer Society (ACS). Prostate cancer is more common in older men and non-Hispanic Black men. Men over the age of 65 accounts for almost 6 out of every 10 cases, but men under the age of 40 are extremely uncommon. Men are diagnosed on average when they are 66 years old.

Obese people may have a higher risk of prostate cancer than people who are considered to be of normal weight, although research has produced mixed results. Prostate cancer can spread to nearby organs, such as bladder, or migrate through bloodstream or lymphatic system to bones or other organs. Pain and shattered bones can be caused by prostate cancer that has spread to the bones. Prostate cancer can still react to treatment and be controlled once it has spread to other parts of the body, but it is unlikely to be cured.

Some major players in the market include AbbVie Inc., Johnson & Johnson Services, Inc., Merck KGaA, SANOFI, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, Anti-Luteinizing Hormone-Releasing is a Luteinizing Hormone-Releasing that has been published and validated for use in IC and IH (P) by Merck KGaA.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- AbbVie Inc., Johnson & Johnson Services, Inc., Merck KGaA, SANOFI,among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global LHRH for Prostate Treatment Market Report by Segment

By Type

• Leuprolide
• Goserelin
• Triptorelin

Global LHRH for Prostate Treatment Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa